Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





PhIII Sonrotoclax+Zanubrutinib w/Venetoclax+Obinutuzumab Pts w/Untx Chronic Lymphocytic Leukemia

Cancer
Catherine Coombs
A Phase III, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Lymphoid Leukemia

Study Description

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Eligibility

If you have Chronic Lymphocytic Leukemia

If you are at least 18 years old.

You cannot participate in this study if you are female who is pregnant or breastfeeding or planning to become pregnant.

You cannot participate in this study if you have uncontrolled hypertension.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.